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ABSTRACT The cytokine tumor necrosis factor a
(TNF-a) alone does not induce classH major histocompatibility
complex (MHC) expression in most primary cells but can
regulate ongoing class I expression in either a positive or
negative fashion. The mechani(s) by which TNF-a enh
interferon y (IFN-'y)-induced class II expression was examined
in a primary cell type, the astrocyte, by transient transfection
of the HLA-DRA promoter linked to a chloramphenicol ace-
tyltransferase reporter gene (DRA-CAT). We show that
TNF-a, while having no effect on its own, can synergize with
IFN-y to increase the level of promoter activity of a DRA-CAT
construct. Three known sequences-W. X, and Y--are re-
quired for TNF-a enhancement of IFN-y-induced promoter
activity. The corollary effect of TNF-a on DNA-binding pro-
teins specific for these elements was examined. A previous
report described a DNA-binding protein, IFN-y-enhanced
factor X (IFNEX), which is upregulated by IFN-y in astrocytes
and is specific for the X box oftheDRA promoter. In this study,
we found that TNF-a alone did not induce any nuclear pro-
teins; however, combined treatment of astrocytes with both
IFN-y and TNF-a induced a DNA-protein complex of slower
electrophoretic mobility than IFNEX. The TNF-a-induced
complex (TIC-X) has specificity for the X element of the DRA
promoter. These results suggest a mechanism by which TNF-a
enhances IFN-y-induced class H MHC expression via the
formation of TIC-X.
Class II antigens are heterodimeric glycoproteins encoded by
genes in the major histocompatibility complex (MHC) which
play a critical role in the induction of immune responses (1).
The constitutive expression of class II MHC antigens is
restricted to B cells, dendritic cells, thymic epithelial cells,
and macrophages (2), although other cell types can express
class II antigens upon exposure to interferon y (IFN-y).
These include fibroblasts (3), pancreatic I cells (4), endothe-
lial cells (5), and astrocytes (6). The proper constitutive and
inducible expression of class II antigens is a crucial deter-
minant in the generation of normal immune responses, and
aberrant class II expression has been implicated in various
autoimmune disorders (7).
IFN--induced class II gene expression is for the most part
transcriptionally regulated. Three cis-acting elements which
are highly conserved between murine and human class II
MHC promoters have been described; from 5' to 3' they are
the W (Z, S, or H), X, and Y elements, respectively, which
are important for both constitutive and IFN-y-induced class
II expression (for reviews see refs. 8 and 9).
Although IFN-y is considered the primary inducer of class
II antigens, tumor necrosis factor a (TNF-a) can both en-
hance and inhibit IFN-y-induced class II expression (10-12).
TNF-a is usually unable to initiate transcription of class II
genes but can either positively or negatively regulate ongoing
class II expression. Few studies have been performed to
understand the mechanism(s) by which TNF-a enhances
IFN--induced class II expression, particularly in primary
cells. This report utilizes primary rat astrocytes for this
reason. Class II MHC expression in the central nervous
system is normally absent, but induced expression on astro-
cytes has been observed in various neurological diseases (for
review see ref. 13).
Previous work has shown that astrocytes express class II
MHC mRNA and protein in response to IFN-y, that TNF-a
alone has no effect on class II expression, and that TNF-a
enhances IFN-y-induced class II expression (10, 14). TNF-a
acts at the transcriptional level to increase IFN-yinduced
transcription of the class II gene as assessed by nuclear
run-on assays and does not act posttranscriptionally to sta-
bilize IFN-rinduced class II mRNA (14). We recently dem-
onstrated that elements within the W, X, andY sequences are
essential for IFN-'y inducibility of the HLA-DRA gene in
astrocytes, and we described a DNA-binding protein, IFN-
-enhanced factor X (IFNEX), which is upregulated by
IFN-y and is specific for the X box (15, 16). We have
extended these studies to examine the molecular mecha-
nism(s) by which TNF-a enhances IFN--induced class II
gene expression. We show that the W, X, and Y sequences
are critical for TNF-a enhancement of IFN-y-induced DRA
gene expression in astrocytes. More importantly, we de-
scribe a DNA-protein complex [TNF-a-induced complex X
(TIC-X)] that is induced by a combined treatment of astro-
cytes with IFN-y and TNF-a and is specific for the X element
of the DRA promoter.
MATERIALS AND METHODS
Recombinant Proteins. Recombinant rat IFN-y was pur-
chased from AMGen Biologicals, and recombinant human
TNF-a was the generous gift of Genentech.
Primary Glial Cell Cultures. Primary glial cell cultures were
established from neonatal rat cerebra (17). Astrocyte cultures
were routinely >97% positive for glial fibrillary acidic pro-
tein, an intracellular antigen unique to astrocytes (18).
Transfection and Chloramphenicol Acetyltranferase (CAT)
Assay. HLA-DRA/CAT gene constructs used in these studies
have been described in detail previously (15, 16) and are
shown schematically in Fig. 1. Transfection of primary rat
astrocytes was performed by electroporation (16) with 15 jig
of plasmid DNA per transfection. Transfected astrocytes
Abbreviations: CAT, chloramphenicol acetyltransferase; hXBP-1,
human X-box-binding protein 1; IFN-y, interferon ay; IFNEX, IFN-
t-enhanced factor X; MHC, major histocompatibility complex;
TNF-a, tumor necrosis factor a; TIC-X, TNF-a-induced complex X;
TIP, TNF-a-induced protein.
ITo whom reprint requests should be addressed.
11518
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Proc. Natl. Acad. Sci. USA 89 (1992) 11519
were either unstimulated or stimulated for 48 hr with IFN-y
(100 units/ml), TNF-a (50 ng/ml), or both and then har-
vested, and protein extracts were prepared (19). CAT activity
was determined by the liquid scintillation counting method of
Seed and Sheen (20). Fold induction of CAT activity after
IFN-yor IFN-y/TNF-a treatment was calculated by dividing
the cpm ofthe IFN-y- or IFN-y/TNF-a-treated sample by the
cpm of the untreated sample.
Nuclear Extracts and DNA Binding Assays. Nuclear ex-
tracts were prepared (16) from astrocytes which were incu-
bated without or with IFN-y (100 units/ml), TNF-a (50
ng/ml), or both for 24 hr. Gel shift assays were performed
(16), using as probes (i) a DNA fragment extending from base
pair (bp) -152 to bp -66 isolated from A-152-WT, (ii) X+Y
oligonucleotide (-110 to -61, 5'-CCCCTAGCAACAGAT-
GCGTCATCTCAAAATATTTTTCTGATTGGCCAAAG-
3'), and MX+Y oligonucleotide (-110 to -61, 5'-CC-
AAGCTACCACTCGTAGTCATCTCAAAATATTTTTCT-
GATTGGCCAAAG-3'). For competition reactions,
nonradioactive competitor was incubated with the nuclear
extract for 5 min prior to the addition of labeled probe.
Reaction mixtures were then electrophoresed at 200 V in 6%
polyacrylamide gels in lx TBE (89 mM Tris base/89 mM
boric acid/2.5 mM EDTA, pH 8.3). The dried gels were
exposed to Kodak XAR-5 film at -700C with intensifying
screens for various times.
RESULTS
Deletion and Substitution Mutants Demonstrate That the W,
X, and Y Elements Are Required for TNF-a Enhanment of
IFN-y-Induced DRA Expression. Previous work has shown
that a 141-bp region of the DRA promoter, including the W,
X, and Y boxes, is required for IFN-y induction of class II
expression in astrocytes (15). To determine which region(s)
of the DRA promoter is needed for the enhancing activity of
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FIG. 1. Effect ofdeletion mutations (A) or site-specific mutations
(B) in the HLA-DRA promoter on inducibility by IFN-y or IFN-y/
TNF-a. Constructs were transiently transfected into astrocytes, and
the cells were treated with medium alone, IFN-y (100 units/ml),
TNF-a (50 ng/ml), or IFN-y plus TNF-a for 48 hr. Data are the
means + SD from 14 experiments (A) or five experiments (B).
pD164-2 and SK+ serve as negative controls; the DRA promoter has
been excised in these plasmids, which contain only the CAT gene.
TNF-a, we used constructs that contained varying lengths of
the 5' end of the DRA promoter (Fig. 1A). These constructs
were transiently transfected into primary rat astrocytes and
tested for their response to IFN-y, TNF-a, or IFN-y plus
TNF-a. In agreement with our previous findings (15), IFN-y
inducibility was maintained down to -141 bp but was lost at
-109 bp (Fig. 1A). TNF-a enhancement of IFN-y-induced
DRA promoter activity exhibited a similar pattern. Cells
treated with IFN-y/TNF-a after transfection with constructs
5'A-1028 and 5'A-141 showed a consistent increase in
promoter activity compared with IFN-y alone, whereas as-
trocytes transfected with construct 5'A-109 showed no
response to IFN-y and no enhancement in the presence of
TNF-a (Fig. 1A). TNF-a alone had no effect on DRA
promoter activity, giving essentially the same activity as
unstimulated controls (data not shown). To define in more
detail regulatory sequence(s) within 141 bp of the DRA
promoter that contribute to TNF-a enhancement of IFN-y-
induced class II expression, we used a set of substitution
mutants that individually affected the W, X, or Y region.
Within the W region there is an authentic Servenius septamer
(S2) (21) flanked by two potential Servenius-like sequences
(S1 and S3) (see Fig. 1B). Mutation ofthe authentic Servenius
sequence (W-M2) resulted in a substantial decrease in IFN-y
inducibility when compared with wild type (Fig. 1B), and also
diminished, but did not abolish, the TNF-a effect. Mutation
of either of the lesser conserved septamers (W-M1 and
W-M3) had no effect on either the IFN-y or the IFN-y/
TNF-a response. Mutations within the Y box that disrupted
the inverse CCAAT motif (Y-M1) completely abolished
IFN-y inducibility and TNF-a enhancement (Fig. 1B).
Within the X region of the DRA promoter, the 5' X, site is
bound by the nuclear protein RF-X (22), while the 3' X2 site
is bound by human X-box-binding protein 1 (hXBP-1) (23).
The wild-type X1 site has the sequence 5'-CCCCTAGCAA-
CAGA-3'. A complete mutation of the X, site (X-M3; 5'-
AGAACTAGTCCAGA-3') abolished the response to both
IFN-y and IFN-y/TNF-a (Fig. 1B). Mutation of the X2 site
(X-M2), which prevents binding of hXBP-1, had no effect on
either induction by IFN-y or enhancement by TNF-a. These
results demonstrate that sequences within the X1 but not X2
site are required for both IFN-y induction and TNF-a en-
hancement ofDRA promoter activity in astrocytes.
IFN-y/TNF-a Induces a Complex That Binds Specifically to
the X Region of the DRA Promoter. We next examined
whether TNF-a induces proteins which bind to the DRA
promoter. Gel shift assays were performed using an oligo-
nucleotide that contained the X+Y sequence (see Fig. 2A for
a description of fragments and oligonucleotides used in the
gel shift assays). The probe was radiolabeled and incubated
with nuclear extracts from astrocytes that had been incubated
with medium alone (untreated), IFN-y, TNF-a, or IFN-y/
TNF-a for 24 hr. A constitutive complex was detected in
extracts from untreated astrocytes (Fig. 2B, lane 1), and
IFN-y enhanced this complex (lane 2, complex 1, IFNEX),
as previously observed (16). IFN-y/TNF-a treatment in-
duced the formation of a complex with slower mobility than
IFNEX (lane 4, complex 2), whereas treatment with TNF-a
alone was comparable to no treatment (lane 3). Competition
with oligonucleotides corresponding to various regions of the
DRA promoter demonstrated that only X+S competed for
complex 1 and 2 formation (Fig. 2C, lanes 8 and 13). These
results indicate that IFN-y/TNF-a induces a nuclear pro-
tein(s) with specificity for the X box of the DRA promoter.
We have tentatively named complex 2 as TIC-X. To better
define the importance of the X region for complex formation,
gel shift assays were performed using an oligonucleotide
containing a mutated X region. Formation of TIC-X was
evident upon incubation with the X+Y probe (Fig. 2D, lane
4) and was blocked by homologous oligonucleotide compet-
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FIG. 2. (A) Restriction fragment and oligonucleotides used as probes and/or competitors in gel shift assays. The WXY probe was cut out
of A-152-WT by using Xba I and Msc I (-152 to -66). All the other probes were synthetic oligonucleotides. Numbers refer to nucleotide
positions relative to the DRA cap site. (B) IFN-y/TNF-a treatment induces a protein(s) which complexes with the X+Y sequence of the DRA
promoter. The X+Y probe (50,000 cpm per lane) was incubated with 10 Ag of the indicated nuclear extract. The gel was exposed to film for
16 hr. (C) Competition experiment. A 100-fold molar excess of the indicated oligonucleotides was incubated with 10 pg of the indicated nuclear
extracts for 5 min before the addition of 50,000 cpm of X+Y probe. The gel was exposed to film for 18 hr. (D) Mutation of the X box abolishes
TIC-X formation. About 40,000 cpm of either the X+Y oligonucleotide (lanes 1-6) or the MX+Y oligonucleotide (lanes 7-9) was incubated
without (lane 7) or with 10 Ag ofnuclear extract from untreated (lanes 1-3, and 8) or IFN-y/TNF-a-treated (lanes 4-6, and 9) primary astrocytes,
in the presence or absence of a 100-fold molar excess of the indicated competitor. The gel was exposed to film for 17 hr.
itor (lane 5), but not by mutated X-region oligonucleotide
MX+Y (lane 6). In addition, TIC-X formation was not seen
when the MX+Y oligonucleotide was used as probe (lane 9).
These data indicate that the X region is critical for TIC-X
formation. In contrast to our previous experience with gel
shift assays which resulted in tight bands (24-26), the com-
plexes reported in this manuscript and by Moses et al. (ref.
16, which describes IFNEX in detail) consistently formed a
diffuse and broad band. We believe this pattern of complex
formation is due to the nature of the nuclear proteins under
study and their interactions with the DRA promoter.
Due to the inherent variability in working with primary
cells, the reproducibility of these findings is critical. Thus, 65
gel shift assays have been performed with nuclear extracts
from 15 different preparations of astrocytes, using multiple
preparations of eight different DNA probes. We have con-
sistently observed the formation of IFNEX and TIC-X.
Kinetic Analysis of IFNEX and TIC-X Formation. We next
examined the time course offormation ofIFNEX and TIC-X.
Astrocytes were exposed to IFN-y or IFN-y/TNF-a for 6,
12, or 24 hr, and nuclear extracts were prepared and analyzed
for binding to the -152 to -66 probe (WXY; see Fig. 2A).
IFNEX was not detected until after a 12-hr stimulation with
IFN-y (Fig. 3A, lane 2) and persisted for at least 24 hr (lane
3). IFNEX was detected after only a 6-hr exposure to
IFN-y/TNF-a (lane 4); however, TIC-X was not observed
B
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after 6 hr. After a 12-hr stimulation, IFNEX was further
enhanced and TIC-X was just barely detectabe (lane 5).
Interestingly, after a 24-hr exposure to IFN-'y/TNE-a, the
TIC-X complex was quite evident whereas IFNEX had
decreased (lane 6). These results suggest that the combined
treatment of astrocytes with IFN-y and TNF- has several
effects with respect to formation ofDNA-protein complexes:
(i) an increase in the amount of IENEX complex compared
with that seen after treatment with IFN-,y alone, (ii) a
decrease in the length of exposure to IFN-y (in the presence
of TNF-a) required for IFNEX complex formation, and (Hi)
the priming of astrocytes by IFN-y so that they respond to
TNF-a stimulation by the formation of a protein(s) [TNF-a-
induced protein (TIP)] that results in the TIC-X complex. To
confirm that an IFN-y priming signal is required for TIC-X
formation, experiments were performed in which nuclear
extracts from IFN-- or TNF-a-treated astrocytes were
mixed and then analyzed for binding to the WXY probe.
Mixing the two extracts did not lead to TIC-X complex
formation (Fig. 3B, lane 3), suggesting that a precursor form
ofTIP was not present in the nuclear extracts from astrocytes
treated with TNF-a alone.
DISCUSSION
In this report, we have analyzed the responsiveness of a
MHC class II promoter, that of the HLA-DRA gene, to the
combined stimuli ofIFN-y plus TNF-a in a primary cell type,
the astrocyte. We show that TNF-a has no effect on its own
but can synergize with IFN-y to increase the promoter
activity of a DRA/CAT construct. The use of substitution
mutants indicates that three sequence elements (W, X, and Y)
are required for TNF-a enhancement of IEN--induc pro-
moter activity. Most crucial, we have correlated the in vivo
functional analysis of DRA regulatory elements with gel
mobility-shift assays for IFN-y/TNF-a-induced DNA-
binding proteins. Specifically, we have identified the forma-
tion of a DNA-protein complex with nuclear extracts from
astrocytes treated with both IFN-yand TNF-a; this complex,
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A study ofTNF-a induction ofthe murine class II gene Aa
has been performed in WEHI-3 cells that differs from our
study Xi that tNF-a alone induced class II gene expression
in this cell line. Linker-scanning mutation of Aa demon-
strated that five promoter elements were neede for TNE-a
induction in WEHI-3 cells (27). These included the three
conserved elements (H, X, and Y), the NF-KB-like enhancer'
and a TNF-a-specific sequence called the T box. The T box
is located between bp -31 and -18 ofAa, downstream from
the Y box. The T-box sequence is important for optimal
induction by TNF-a, but not IFN-y. However, the full T-box
sequence is found only in the Aa and DQA promoters.
TNF-a induces several transcription factors, including
AP-1 and NF-KB. In primary astrocytes, TNF-a induces
expression of the interleukin 6 gene, which is accompanied
by a rapid and transient increase in the appearance of an
NF-KB-like protein (26). Indications that TIC-X is not related
to NE-KB include (i) a functional NF-KB biding site is not
observed in the region of the DRA promoter under study; (ii)
the appearance of NF-KB is rapid (within 15 min and lasting
for 1-2 hr), while that ofTIC-X is slow (optimal at 24 hr); (iii)
NF-KB is activated by TNF-a alone, whereas TIC-X expres-
sion requires both IFN-y and TNF-a; and (iv) an oligonu-
cleotide containing the NF-KB sequence does not compete
for the formation of TIC-X (data not shown).
TNF-a causes the transcriptional activation of c-Jun and
c-Fos, which together constitute the nmor components of
AP-1 (28). A c-Jun-like protein which an form a heterodimer
with c-Fos or a related protein has been identified and cloned
(23, 29). This protein, hXBP-1, binds tothe X2 siteoftheDRA
promoter, which is almost a perfect match to the phorbol
ester response element consensus sequence (23). Our trans-
fection studies show that mutations in the hXBP-1 binding
site (X-M2) have no effect on the IFN-y or IFN-Y/TNF-a
response, thus negating the possible involvement of hXBP-1
in DRA regulation by IEN-y/TNF-a in the astrocyte.
TIC-X formation is induced only by a combined treatment
with IEN-y plus TNF-a, and the appearance ofTIC-X occurs
in a delayed, time-dependent manner. These findings suggest
that astrocytes require a priming signal initiated ItPN-Iy,
FIG. 3. (A) Kinetic analysis of
the effect of IPN-y or IFN-Y/
TNF-a treatment on astrocyte
formation of IFNEX and TIC-X.
Nuclear extracts were prepared
from primary astrocytes treated
with either IPN-y or IFN-y/
TNF-a for 6, 12, and 24 hr. The
WXY (wild-type, WT) probe
(60,000 cpm per lone) was incu-
bated with 10 Ag of nuclear ex-
tract. Lanes 1-3, IFN--treated
extract; lanes 4-6, IFN-y/TNF-
a-treated extract; lanes 7 and 8,
IFN-Y- or IFN-Y/TNF-a-treated
extracts plus a 100-fold molar ex-
cess ofWT competitor DNA. The
gel was exposed to fihi for 18 hr.
(B) Gel shift anaysis of nuclear
4 {>rP[ -X extracts from IFN-7 or TNF-a-
treated astrocytes mixed to-
gether. The WXY (WT) probe
(60,000 cpm per lane) was incu-
bated-, with 10 lag of TNF-a-
treated extract (lane 1), 10 jg of
IFN-treated extract (lane 2), or
5 gsg of TNF-a-treated extract
plus S AgofIFN-7treated extract
(lane 3). The gel was exposed to
film for 12 hr.
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which then renders the astrocyte responsive to TNF-a,
resulting in the subsequent formation ofTIC-X. As shown by
gel shift analysis, both IFNEX and TIC-X bind to the same
region of the DRA promoter, and the appearance ofTIC-X is
generally accompanied by a decrease and/or disappearance
in IFNEX. These data suggest that TIC-X may result from an
interaction ofDNA with IFNEX, and subsequently with TIP,
leading to the appearance of the higher molecular weight
complex, TIC-X. Preliminary UV crosslinking studies with a
bromodeoxyuridine-substituted WXY probe indicate that
there are no differences between extracts prepared from cells
stimulated with IFN-y or IFN-y/TNF-a in either the number
or the sizes ofproteins which are directly interacting with the
DNA. This suggests that TIP does not bind directly to DNA
but in all likelihood binds to a DNA-IFNEX complex, and
thus leads to TIC-X formation. These results do not exclude
the possibility that TIC-X may actually be an IFNEX homo-
multimer. Both these interpretations are compatible with the
data from transfection studies showing that as long as some
responsiveness to IFN-y is observed, TNF-a enhances pro-
moter activity, but when the IFN-y response is completely
lost, there is no longer TNF-a enhancement. It is also
possible, however, that IFNEX and TIP bind to different
regions of DNA within the X box.
We propose a tentative model for TNF-a enhancement of
IFN-y induced class II MHC promoter activity and TIC-X
formation (Fig. 4). Under basal conditions, astrocytes con-
tain low levels ofa constitutive protein which appears to bind
to the X box; however, the class II promoter is transcrip-
tionally inactive (a). An IFN-y enhanced complex (IFNEX)
is observed upon treatment with IFN-y, which may represent
an enhancement of either the binding activity or expression
of the constitutive DNA-binding protein, resulting in tran-
scriptional activation of the class II promoter (b). TNF-a
treatment alone does not modify expression of the constitu-
tive protein or activate transcription (c). Upon IFN-y/TNF-a
treatment, IFNEX is detected initially, and subsequently
TIC-X is expressed. We hypothesize that IFN-y, in addition
to intensifying the IFNEX signal, also provides a priming
signal to the astrocyte so that this cell is now responsive to
TNF-a stimulation. TNF-a in this setting induces the ex-
pression of TIP, which may interact with IFNEX, resulting
in a DNA-IFNEX-TIP complex which most likely corre-
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FiG. 4. Model for IFN-y and TNF-a activation of the HLA-DRA
promoter. C, constitutive nuclear protein; stippled box, Y-box-
binding protein; PRE, preinitiation complex.
The requirement ofthree cis-acting elements (W, X, and Y)
for IFN-- and IFN-y/TNF-a-mediated class II MHC gene
expression suggests that factors binding to these elements
may interact with one another. Thus far, by gel shift analysis,
we have not observed any complexes binding to the W box
alone (data not shown); DNase footprinting analysis will
determine whether there are factors other than the X-box-
binding proteins present. A number of elements and tran-
scription factors are likely to mediate the induction of class
II expression following IFN-y treatment, and its enhance-
ment by TNF-a. IFNEX, TIP, and TIC-X may have a critical
role in this process.
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